TrialRMD open2023

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Dinesh Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.